Rigel Pharmaceuticals
- Country
- 🇮🇳India
- Ownership
- -
- Employees
- 147
- Market Cap
- -
- Introduction
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Study of Olutasidenib and Temozolomide in HGG
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT06161974
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Susan Chi, Boston, Massachusetts, United States
🇦🇺Perth Children's Hospital, Perth, Western Australia, Australia
Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS)
- Conditions
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT05308264
- Locations
- 🇺🇸
University of Texas, Southwestern, Dallas, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Mount Sinai Medical Center, Miami Beach, Florida, United States
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT04904276
- Locations
- 🇺🇸
Saint Agnes Hospital, Baltimore, Maryland, United States
🇺🇸New York Medical College, Valhalla, New York, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 280
- Registration Number
- NCT04629703
- Locations
- 🇧🇷
Hospital Luxenburgo-Associação Mário Penna, Belo Horizonte, Minas Gerais, Brazil
🇧🇷Irmandade da Santa Casa de Misericórdia de Porto Alegre - ISCMPA, Porto Alegre, Rio Grande Do Sul, Brazil
🇺🇸Alternative Research Associates, LLC, Miami, Florida, United States
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT04138927
- Locations
- 🇺🇸
University of Southern California - Janice and Robert Hall Clinical Trials Biospecimen Laboratory, Los Angeles, California, United States
🇺🇸Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
- Conditions
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT03764618
- Locations
- 🇺🇸
Piedmont Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇦🇺Concord Repatriation General Hospital, Sydney, New South Wales, Australia
Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP
- Conditions
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Rigel Pharmaceuticals
- Registration Number
- NCT03363334
A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)
- Conditions
- Interventions
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT02612558
- Locations
- 🇺🇸
MidMichigan Health Cancer Center, Midland, Michigan, United States
🇺🇸Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
🇺🇸Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Rigel Pharmaceuticals
- Registration Number
- NCT02433236
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT02112838
- Locations
- 🇺🇸
Southeast Renal Research Institute, Chattanooga, Tennessee, United States
🇦🇹Medical University Vienna, Nephrology, Vienna, Austria
🇨🇳China Medical University Hospital, Taichung, Taiwan